Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Modular, Open Label, Dose Finding, Phase 1/2 Clinical Trial in Patients With Solid Tumours to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of PTT-4256

Next Previous
Trial Profile

A Modular, Open Label, Dose Finding, Phase 1/2 Clinical Trial in Patients With Solid Tumours to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of PTT-4256

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Aug 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary) ; PTT 4256 (Primary)
  • Indications Cervical cancer; Colorectal cancer; Gastric cancer; Malignant melanoma; Non-small cell lung cancer; Prostate cancer; Renal cell carcinoma; Solid tumours; Triple negative breast cancer
  • Focus Adverse reactions; First in man
  • Acronyms RAISIC-1
  • Sponsors Pathios Therapeutics

Most Recent Events

  • 06 Aug 2026 Planned number of patients changed from 30 to 150.
  • 02 Jun 2026 Results presented at the 62nd Annual Meeting of the American Society of Clinical Oncology
  • 20 Nov 2024 According to a Pathios Therapeutics media release, the RAISIC-1 trial is being run by the Australian-based team at Pathios Therapeutics Pty Ltd, in partnership with key Australian clinical trial sites and collaborators, contract research organisations and M:M Bio Pty Ltd, part of the global Molecule to Medicine (MTM) ecosystem of companies.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top